1. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2

   • Yilong Zhang
   • Yousheng Hua
   • Kenneth K. Chan

   Original Article 14 March 2006 Pages: 561 - 569

   

2. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer

   • Yasushi Sato
   • Tetsuji Takayama
   • Yoshiro Niitsu

   Original Article 04 February 2006 Pages: 570 - 576

   

3. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells

   • Baoli Qin
   • Hiroshi Ariyama
   • Shuji Nakano

   Original Article 11 March 2006 Pages: 577 - 584

   

4. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation

   • Giacomo Allegrini
   • Antonello Di Paolo
   • Alfredo Falcone

   Original Article 06 May 2006 Pages: 585 - 593

   

5. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

   • Seiji Nagashima
   • Hiroshi Soda
   • Shigeru Kohno

   Original Article 07 March 2006 Pages: 594 - 600

   

6. A phase I trial of carboplatin and etoposide for elderly (≥75 year-old) patients with small-cell lung cancer

   • Minoru Fukuda
   • Hiroshi Soda
   • Mikio Oka

   Original Article 04 February 2006 Pages: 601 - 606

7. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging

   • Ruediger E. Port
   • Christian Schuster
   • Peter Bachert

   Original Article 28 February 2006 Pages: 607 - 617

   

8. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells

   • Annie Hurtubise
   • Richard L. Momparler

   Original Article 17 June 2006 Pages: 618 - 625

   

9. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy

   • Demiana William Faltaos
   • Jean Sebastian Hulot
   • Philippe Lechat

   Original Article 10 March 2006 Pages: 626 - 633

   

10. A phase II trial of O ⁶-benzylguanine and carmustine in patients with advanced soft tissue sarcoma

    • Christopher W. Ryan
    • M. Eileen Dolan
    • Everett E. Vokes

    Original Article 07 March 2006 Pages: 634 - 639

    

11. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M₄N and maltose-M₃N, and their use in combination with doxorubicin or paclitaxel

    • Chih-Chuan Chang
    • Yu-Chuan Liang
    • Ru Chih C. Huang

    Original Article 17 March 2006 Pages: 640 - 653

    

12. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

    • Her-Shyong Shiah
    • Yee Chao
    • Tsang-Wu Liu

    Original Article 07 March 2006 Pages: 654 - 664

    

13. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro

    • Taisuke Mori
    • Yoshiyuki Kinoshita
    • Hideo Honjo

    Original Article 14 March 2006 Pages: 665 - 672

    

14. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

    • A. Felici
    • W. J. Loos
    • M. J. A. de Jonge

    Original Article 17 March 2006 Pages: 673 - 680

    

15. Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib

    • Juan Jose Perez-Ruixo
    • Peter Zannikos
    • Vladimir Piotrovsky

    Original Article 17 March 2006 Pages: 681 - 691

    

16. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor

    • Omar N. Al Safarjalani
    • Reem Rais
    • Mahmoud H. el Kouni

    Original Article 10 March 2006 Pages: 692 - 698

17. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice

    • Anna M. E. Bruynzeel
    • Paula P. N. Mul
    • Wim J. F. van der Vijgh

    Original Article 25 March 2006 Pages: 699 - 702

18. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

    • G. Goss
    • L. L. Siu
    • L. K. Seymour

    Clinical Trial Report 10 March 2006 Pages: 703 - 710

19. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

    • Panagiotis A. Konstantinopoulos
    • Gerasimos P. Vandoros
    • Athanasios G. Papavassiliou

    Short Communication 25 January 2006 Pages: 711 - 715

    

20. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor

    • Michael Froehner
    • Bettina Beuthien-Baumann
    • Manfred P. Wirth

    Short Communication 01 February 2006 Pages: 716 - 718